Manufacturer: Vardenafil is a first-line treatment for erectile dysfunction

Manufacturer：Vardenafil is the first-line treatment for erectile dysfunction in the treatment of male erectile dysfunction. Developed by Bayer, Germany, and first listed in the US in 2002. Like sildenafil, it is a second-generation type 5 phosphodiesterase inhibitor that works very quickly and works for about 15 to 20 minutes.

It is ten times more powerful than sildenafil. Clinical data show that 50% to 60% of men with diabetes over 50 years of age have erectile dysfunction, and erectile dysfunction caused by neurological and vascular damage caused by diabetes is particularly difficult to treat. The potent selective phosphodiesterase 5 (PDE5) inhibitor vardenafil developed by Bayer may bring good news to patients with erectile dysfunction caused by diabetes. These drugs are used as a one-time treatment drug.

After oral administration for about 1 hour before sex, the concentration of CGMP is reduced by selective inhibition of PDE5, and the release of cGMP induced by nitric oxide (NO) released after sexual stimulation is increased. Smooth muscle, enhance erectile function, occasional adverse reactions such as headache, blush, stomach discomfort, color vision disorder.
Three selective phosphodiesterase type 5 (PDE5) inhibitors: sildenafil (Cylix), vardenafil hydrochloride (Elida) and tadalafil are first-line drugs for the treatment of ED; In terms of efficacy, safety and tolerability, PDE5 inhibitors are not significantly different from apomorphine; intracavernous injection of prostaglandin E1 is a second-line treatment for ED; and intrauterine administration of prostaglandin E1 is more effective than intracavernous Prostaglandin E1 was poorly injected. Conclusion PDE5 inhibitors are effective, well tolerated and safe in the treatment of ED. Apomorphine, intracavernous injection of prostaglandin E1 and intraurethral administration of prostaglandin E1 are also effective and have good results. Tolerance.